Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform
Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera Pharma is a Danish biotech company -developing innovative small-molecule and RNA-based therapeutics to address neurological disorders. Their unique R&D model integrates their team of experienced neuroscience drug hunters with cutting-edge technology, like Abzu’s […]